cisplatin + cyclophosphamide + cytarabine + dexamethasone + doxorubicin + prednisone + rituximab + vincristine

This is a multi-agent chemotherapy and immunotherapy combination regimen composed of eight drugs: - **Cisplatin** (a platinum-based DNA crosslinking agent) - **Cyclophosphamide** (an alkylating agent) - **Cytarabine** (a nucleoside analog antimetabolite) - **Dexamethasone** and **Prednisone** (synthetic glucocorticoid corticosteroids with anti-inflammatory and immunosuppressive effects) - **Doxorubicin** (an anthracycline antibiotic that intercalates DNA and inhibits topoisomerase II) - **Rituximab** (a monoclonal antibody targeting CD20 on B lymphocytes, mediating cell lysis via immune mechanisms) - **Vincristine** (a vinca alkaloid that inhibits microtubule formation) This combination brings together agents from several mechanistic classes to maximize cytotoxicity against malignant cells, particularly in hematologic malignancies. While regimens containing subsets of these drugs—such as R-CHOP or R-hyperCVAD—are established for treating aggressive B-cell lymphomas, the exact eight-drug combination listed here is not a standard named protocol but represents an intensive approach likely used in refractory or high-risk cases. Each component has FDA approval for cancer treatment; combinations are tailored based on disease subtype, patient status, and prior therapies[1][2][4][6].